Myelofibrosis 2021 Wrap-Up

Patients with myelofibrosis who are intolerant, refractory to, or ineligible for JAK inhibitor therapy such as ruxolitinib are generally difficult to treat and have poor prognoses. Evidence suggests pelabresib can safely and effectively improve clinical outcomes in this patient subset. Read More ›

For patients with myelofibrosis, fedratinib has emerged as another option for first-line therapy after prior ruxolitinib therapy. In a real-world setting, data indicate earlier initiation of fedratinib may be of clinical benefit in this patient population. Read More ›

Previous studies have established a role for TGFβ in promoting development and progression of myelofibrosis. Evidence suggests AVID200, a TGFβ1/3 inhibitor, may modulate TGFβ signaling mechanisms associated with myelofibrosis. Read More ›

Fedratinib, a JAK2 inhibitor, was recently approved to treat myelofibrosis in patients previously treated with ruxolitinib. Evidence suggests fedratinib may be a viable therapeutic option to improve survival in this patient population. Read More ›

The rate of thrombus formation in patients with myelofibrosis is not well-defined. The intersection of IPSS score and JAK mutation may reliably indicate risk of vascular events in these patients. Read More ›

Evidence suggests fedratinib, a selective JAK2 inhibitor, demonstrates safety and efficacy in patients with myelofibrosis previously treated with ruxolitinib with appropriate mitigation strategies. Read More ›

Patients with advanced myelofibrosis and heavy mutation burden have limited safe and effective therapeutic options. Preliminary clinical trial evidence indicates bomedemstat provides clinical benefit to patients in this population. Read More ›

Patients with a low platelet count represent a difficult-to-treat group because ruxolitinib treatment is typically first-line therapy for myelofibrosis and is associated with suboptimal or loss of response and thrombocytopenia. Parsaclisib may be an effective add-on option for this patient subgroup. Read More ›

FREEDOM2 is the first trial to compare fedratinib to best available therapies, including ruxolitinib and other JAK inhibitors, in patients with myelofibrosis who were previously treated with ruxolitinib for at least 3 months. Read More ›

The rate of thrombus formation in patients with myelofibrosis is not well-defined. The intersection of IPSS score and JAK mutation may reliably indicate risk of vascular events in these patients. Read More ›